Napoleone Ferrara

This biography of a living person needs additional citations for verification. Please help by adding reliable sources. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libelous. Find sources: "Napoleone Ferrara" – news · newspapers · books · scholar · JSTOR (January 2009) (Learn how and when to remove this message)

Napoleone Ferrara (born 26 July 1956 in Catania) is an Italian-American molecular biologist who joined University of California, San Diego Moores Cancer Center in 2013 after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age-related macular degeneration (AMD), and diabetic retinopathy.^[1] At Genentech, he discovered VEGF—and made the first anti-VEGF antibody—which suppresses growth of a variety of tumors. These findings helped lead to development of the first clinically available angiogenesis inhibitor, bevacizumab (Avastin), which prevents the growth of new blood vessels into a solid tumor and which has become part of standard treatment for a variety of cancers.^{[citation needed]} Ferrara's work led also to the development of ranibizumab (Lucentis), a drug that is highly effective at preventing vision loss in intraocular neovascular disorders.^{[citation needed]}

Ferrara received his medical degree from the University of Catania, Italy, in 1981, and joined Genentech in 1988. He did his postdoctoral research at University of California, San Francisco.^[2]

At UC San Diego Moores Cancer Center, Ferrara, a member of the National Academy of Sciences since 2006, serves as Senior Deputy Director for Basic Science and is a Distinguished Professor of Pathology in the UC San Diego School of Medicine, where he will continue cancer drug research targeting angiogenesis.^{[citation needed]} He is presently focusing on investigating mechanisms of tumor angiogenesis alternative to VEGF, in particular the role of factors produced by myeloid cells and fibroblasts in mediating resistance to VEGF inhibitors.^{[citation needed]}

For his VEGF discovery, he won a Lasker Award in 2010.^[3] In 2013, he was awarded the $3 million Breakthrough Prize in Life Sciences for his work.^[4] He has received numerous other awards, including the General Motors Cancer Research Award (2006), the ASCO Science of Oncology Award (2007), the Pezcoller Foundation/AACR International Award (2009), the Dr. Paul Janssen Award for Biomedical Research (2011), and The Economist's Innovation Award for bioscience in 2012.^{[citation needed]} Grand Prix scientifique de la Fondation Lefoulon-Delalande in 2005.^[5]

In September 2014, Ferrara was awarded the António Champalimaud Vision Award, awarded by the Champalimaud Foundation.^[6]

2023, Keio Medical Science Prize.^[7]

This article about an Italian biologist is a stub. You can help Wikipedia by expanding it.

• v
• t
• e